Zika Vaccines Market Is Expected To Witness Significant Growth, Due To High Incidence of Zika Virus Infection

 

The Zika vaccines market is expected to witness significant growth, due to high incidence of Zika virus infection. In November 2019, The European Centers for Disease Control confirmed the first three cases of Zika that started in southern France. Zika is spread mostly by the bite of an infected Aedes species mosquito. These mosquitoes bite during the day and night. Recently, there have been clusters of cases of meningitis, encephalitis, meningitis and other neurological conditions caused by the disease. There are also links to birth defects and neurological problems in some of the babies born to infected mothers. Such concerns are expected to aid in growth of the Zika vaccines market.   

R&D of new products is expected to aid in growth of the Zika vaccines market. Currently, a licensed product, in the form of a live virus extract, is under clinical trials. A Zika vaccine is targeted at preventing the complications and symptoms of pregnancy-related Zoonotic infections caused by the strain of Aedes species. Since it is generally associated with an airborne infection, it was assumed that a vaccine would be needed to prevent infection during pregnancy. There have been no clinical trials testing the safety of this vaccine in pregnant women, however, since the product's development stage involves both in vitro and in silico technologies.

North America Zika vaccines market is driven by R&D of new products. The Canadian Pest Management Regulatory Authority is currently evaluating four related Zika virus vaccines in development. The first is a type 2 injectable vaccine intended for women of childbearing age; the second is a vehicle injected in kittens that prevent the infection from occurring in kittens that are not immunized; the third is a whole virus product designed to be administered to pregnant mothers; and the fourth is an in vitro cell culture product aimed at preventing the infection in cell cultures. These vaccines are currently being evaluated in phase 1 clinical trials. No medication has been proven to stop or prevent the spread of the zika virus, but vaccines can reduce the risk to infants and mothers when infected.

The clinical trial procedures vary according to the type of product being tested. In the case of the in-vitro zika virus vaccine candidates, which are manufactured in the laboratories and then distributed by means of nasal trays into the nasal cavity, the primary test procedure involves exposing the vaccines to irritants and then monitoring the reaction of the mice for approximately two hours post-exposure. The product is expected to be able to protect mice from infection if at least one injection is successful.

Starpharma Holdings Limited Received a Patent for SPL7013 Ophthalmic Drops for Viral Conjunctivitis Drugs Market

 

The growing incidence of viral conjunctivitis cases is driving the growth of the viral conjunctivitis drugs market. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S. Additionally, a rising number of research and development activities for enhancing the effectiveness of viral conjunctivitis drugs is again projected to accelerate the growth of the market. For instance, in 2019, iVIEW Therapeutics Inc., a clinical-stage ophthalmology drug development company, announced the dosing of the first patient in Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis.

In 2018, Starpharma Holdings Limited, a company headquartered in Australia, received a patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections

In April 2020, Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation for diseases and conditions of the eye, announced topline results from its Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA® for the treatment of ocular itching associated with allergic conjunctivitis (AC).

North America is expected to hold a dominant position in the global viral conjunctivitis drugs market due to growing product approval in the region. For instance, on February 23, 2021, Bausch + Lomb launched Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. It is indicated to relieve eye itchiness caused due to conjunctivitis. Moreover, it is the first over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the U.S. Food and Drug Administration (FDA).

Viral conjunctivitis can result from a viral infection with one or more known fungal pathogens. Commonly, the infections are caused by Staphylococcus aureus, which is found commonly in the eyes; the nose, throat, and sinuses. A group of related species also cause systemic infection of the skin, lungs, and blood vessels. These species include E. coli, which is responsible for food poisoning, and the common respiratory tract infection flu. Other yeasts also produce conjunctivitis, including Candida albicans, which causes infections of the bladder and other mucous membranes. Apart from antiviral agents, the global conjunctivitis market is also flooded with topical agents such as steroids, salicylic acid, and azelaic acid.

Increasing Prevalence of Chronic Diseases to Augment Growth of the Specialty CRO's Market

 

Specialty CROs Market

A contract research organization (CRO) is a specialized business that provides specialized support to the biotechnology, pharmaceutical, and health science sectors in the form of contract clinical research services on a contract basis. CRO's are generally formed as an association between two or more pharmaceutical corporations, who mutually decide to engage in joint research and development activities to develop drugs against various fatal diseases and also to find methods of handling such fatal diseases. CRO's play an important role in resolving the problem of development of essential medicines and also in finding alternate routes of delivery of drugs. Specialty CRO's helps biotech and pharmaceutical firms to launch novel therapies in the quickest possible time.

Market Dynamics:

Increasing research and development (R&D) activities and growing R&D expenditures are expected to propel the growth of the specialty CRO's market. For instance, in March 2021, Innoforce and dMed, a clinical CRO, signed an agreement to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.

Moreover, the increasing prevalence of chronic diseases, such as diabetes, cancer, and heart disease, worldwide is expected to augment the specialty CRO's market growth. According to World Health Organization (WHO), chronic diseases are the leading causes of death and disability worldwide.

Furthermore, increasing demand of outsourcing analytical testing and clinical trial services and increase in clinical trials is also expected to fuel the market growth. However, regulatory pressure on CROs and rising instances of drug failure during clinical trial phase are expected to restrain the specialty CRO's market growth.

Competitive Analysis:

Major players operating in the specialty CRO's market are Aclires, Velesco Pharmaceutical Services, SAGE Labs, Gateway Pharmacology Laboratories, DaVita Clinical Research, David H Murdock Research Institute, Afraxis, DATATRAK International, Accelovance, Cytespace Africa, Acquipharma, Profil Abiogenesis Clinpharm, Charles River Laboratories, and Accell Clinical Research.

Major players in the market are adopting various inorganic growth strategies, such as merger and acquisition, to strengthen their market position. For instance, in March 2021, NAMSA (North American Science Associates, Inc.) announced its acquisition of American Preclinical Services (APS), a full service preclinical CRO. This purchase follows NAMSA’s acquisition of Syntactx, New York-based CRO, in January 2021.

In March 2021, PsyBio Therapeutics initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc.

In February 2021, Ingenuity BioScience and Somru BioScience announced the establishment of an innovation-centric bio-analytical laboratory in Ahmedabad, India.

 

High Prevalence of Brain Tumor and R&D of New Drugs to Augment Growth of Anaplastic Astrocytoma Treatment Market

 

Anaplastic Astrocytoma Treatment

High prevalence of brain tumor is expected to propel growth of the anaplastic astrocytoma treatment market. For instance, according to The Central Brain Tumor Registry of the United States (2020 CBTRUS Statistical Report), the incidence rate of all primary malignant and non-malignant brain and other central nervous system tumors in the U.S was 23.79 cases per 100,000 for a total count of 415,411 incident tumors.

Moreover, R&D of new drugs is also expected to aid in growth of the market. For instance, in April 2020, Mateon Therapeutics Inc. announced the publication of a peer-reviewed research article reporting the analysis of the long-term follow-up data on the recalcitrant/resistant anaplastic astrocytoma patient subpopulation treated in the NCT00431561 study, in the oncology journal Cancer Reports and Reviews. Similarly, in December 2020, KIYATEC, Inc. announced the first clinical use of its response-prediction test to improve outcomes in relapsed brain cancer patients.

Adoption of combination therapies is expected to offer lucrative growth opportunities for players in the anaplastic astrocytoma treatment market. For instance, in January 2021, Adastra Pharmaceuticals announced that its Phase Ib trial of oral small molecule drug zotiraciclib in combination with the current standard of care, temozolomide, deminstrted positive results in the treatment of patients with recurrent high-grade gliomas (recurrent anaplastic astrocytoma and recurrent glioblastoma). Moreover, increasing number of treatment centers for brain tumors is also expected to aid in growth of the market. For instance, in March 2020, MagForce AG, a developer of medical devices that generate magnetic hyperthermia to treat cancer, and the Hufeland Klinikum GmbH, a provider of general medical and surgical hospital services, announced the conclusion of a joint cooperation agreement and the planned opening of a NanoTherm treatment center for brain tumors at the Mühlhausen site in Thuringia, Germany.

The anaplastic astrocytoma treatment market is witnessing increasing investment for R&D in the treatment of anaplastic astrocytoma. For instance, in October 2020, Orbus Therapeutics Inc. raised US$ 71 million in Series A financing for R&D in the treatment of anaplastic astrocytoma.

Competitive Analysis

Major players operating in the anaplastic astrocytoma treatment market include, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Adastra Pharmaceuticals, KIYATEC, Inc., Mateon Therapeutics Inc., Orbus Therapeutics Inc., Mylan N.V., Pfizer, Inc., and Novartis AG.

Major players operating in the anaplastic astrocytoma treatment market are focused on R&D to expand their product portfolio. For instance, in March 2021, Orbus Therapeutics Inc. announced a positive outcome of the pre-planned interim analysis for futility in its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma.

Vaccine Contract Manufacturing Market is Growing Rapidly with Moderna collaborating with Catalent Inc. for Fill-Finish manufacturing of Moderna’s COVID-19 vaccine candidate

 

Vaccine Contract Manufacturing

Contract manufacturing is a complex process involved in producing vaccine products. This type of production usually involves the manufacturing of vaccines in a single step. Contract manufacturers usually produce vaccines at their facilities; however, some contract manufacturers also service the field through the provision of workspace and by taking care of the closing storage and final disposition of finished products. Some contract manufacturers specialize in the manufacture of one or few vaccines. Others manufacture vaccines for a number of diseases.

Technological developments in biomanufacturing and biotechnology are expected to drive growth of the global vaccine contract manufacturing market. Biotechnology has witnessed significant growth in the recent past in both developed and emerging economies. According to the India Brand Equity Foundation (IBEF), the Indian biotechnology industry was valued at US$ 63 billion in 2019 and is expected to reach US$ 102 billion by 2025, registering a CAGR of 10.9%. Besides, key biotechnology and pharmaceutical companies are focused on launching vaccines for protection against infectious diseases. For instance, in December 2020, Moderna Inc., a U.S.-based biotechnology company, received the U.S. Food and Drug Administration (FDA) approval for the use of an mRNA-1273 vaccine against COVID-19 in individuals aged 18 years and above. Hence, such factors are expected to drive growth of the global vaccine contract manufacturing market. Furthermore, rising awareness regarding vaccines and their benefits in emerging economies is expected to propel the global vaccine contract manufacturing market growth in the near future.

High cost associated with equipment used in vaccine manufacturing is expected to restrain growth of the global vaccine contract manufacturing market growth in the near future. Among regions, North America is expected to witness significant growth in the global vaccine contract manufacturing market. This is owing to growing presence of major biopharmaceutical companies in the U.S. and Canada. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to increasing R&D activities in emerging economies such as China and India.

Key companies involved in the global vaccine contract manufacturing market are Catalent, Inc., Lonza, Cobra Bio, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Paragon Bioservices, Inc., Ajinomoto Althea, Inc., PRA Health Sciences, Cytovance Biologics, IDT Biologika GmbH, and Albany Molecular Research, Inc.

For instance, in June 2020, Moderna Inc., a U.S.-based biotechnology company, collaborated with Catalent Inc. for Fill-Finish manufacturing of Moderna’s COVID-19 vaccine candidate.     

Metastatic Osteosarcoma Treatment Market Is Expected to Grow Rapidly With Innova Therapeutics Inc. Receiving the U.S. FDA Rare Pediatric Disease Designation for IVT-8086 Indicated for the Treatment of Osteosarcoma

 

Metastatic Osteosarcoma Treatment

Metastatic osteosarcoma is one form of the disease osteoarthritis. It has been found that this disease occurs due to a problem with the cells in the spinal cord that are responsible for the proper function of the joints. The disease generally affects the aging group and those individuals suffering from other medical conditions like diabetes etc. The pain caused due to metastatic osteosarcoma can be so severe that it leads to tremendous disability to the affected person.

Increasing drug pipeline for malignant bones and soft tissue cancer is expected to drive growth of the global metastatic osteosarcoma treatment market. Key biopharmaceutical and pharmaceutical companies are focused on research and development activities to synthesize novel drug treatment for soft tissue and malignant bone cancer. For instance, in September 2020, Junshi Biosciences, a major biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) Orphan Drug designation to Toripalimab for the treatment of soft tissue sarcoma. Furthermore, in January 2020, Epizyme, a U.S.-based biopharmaceutical company, received the U.S. FDA approval for Tazverik indicated for the treatment of a rare type of soft tissue sarcoma that's spread and can't be treated with surgery. Hence, these factors are expected to drive growth of the global metastatic osteosarcoma treatment market. Furthermore, growing government initiatives to raise awareness regarding bone cancer is expected to propel the global metastatic osteosarcoma treatment market growth in the near future.

High costs associated with cancer therapies coupled with the presence of alternative therapies such as new forms of radiation therapy are expected to hamper the global metastatic osteosarcoma treatment market growth in the near future. Besides, stringent approval policies are expected to restrain growth of the market. Among regions, North America is expected to witness significant growth in the global metastatic osteosarcoma treatment market. This is owing to a high prevalence of metastatic osteosarcoma in the region. According to the American Cancer Society (ASC), around 1,000 new cases of osteosarcoma are diagnosed in the U.S. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to improving healthcare infrastructure in the region.

Key players involved in the global metastatic osteosarcoma treatment market are Luitpold Pharmaceuticals Inc., Mylan Laboratories Limited, Dr. Reddy’s Laboratories Ltd., Alvogen Inc., Sun Pharmaceutical Industries Ltd., Gland Pharma Limited, Innova Therapeutics Inc., and Sagent Pharmaceuticals Inc.

For instance, in October 2020, Innova Therapeutics Inc., a biotechnology company, received the U.S. FDA rare pediatric disease designation for IVT-8086 indicated for the treatment of osteosarcoma.

Rapid Approvals of New Therapies to Augment the Major Depressive Disorder (MDD) Treatment Market Growth

 

Major Depressive Disorder Treatment

Major depressive disorder, also called clinical depression, is an extremely serious psychiatric disorder characterized by at least 2 weeks of persistent, severe, and unpredictable low mood. Loss of interest in normally pleasurable activities, lowered self-esteem, low energy, aches and pains without a definite cause, and feelings of worthlessness and guilt are typical symptoms.

Diagnosis usually depends on the medical history of the patient and is made according to the Diagnostic and Statistical Manual for Mental Disorders IV-TR, which lists disorders in three categories based on the extent of the symptoms, the signs or symptoms, the time period they last for, the reaction of the patient to normal situations, and the patient's reaction to stress.

Market Dynamics:

Rapid approvals of new therapies from regulatory bodies, such as the United States Food and Drug Administration and the European Commission, are expected to augment the growth of the major depressive disorder (MDD) treatment market. For instance, in February 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has authorized the use of SPRAVATO (esketamine nasal spray), co-administered with oral antidepressant therapy in adults with a moderate to severe episode of major depressive disorder (MDD), as acute short term treatment, for the rapid reduction of depressive symptoms.

Moreover, increasing prevalence of MDD, especially in North America, is expected to propel the growth of the major depressive disorder (MDD) treatment market. MDD is one of the most common mental health disorders in the United States. For instance, according to the Anxiety and Depression Association of America (ADAA), MDD affects more than 16.1 million American adults, or about 6.7% of the U.S. population age 18 and older.

Increasing awareness about various depression episodes and the growing geriatric population worldwide is expected to offer lucrative growth opportunities for players in the market.

Competitive Analysis:

Major players operating in the major depressive disorder (MDD) treatment market are Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline, Merck & Co., AstraZeneca Plc., Pfizer, Johnson & Johnson, Lundbeck, Alkermes, Allergan, and Takeda Pharmaceutical Company Limited.

In February 2021, Otsuka and Click Therapeutics announced the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD).

In February 2021, MYND Life Sciences Inc. signed a Collaborative Research Agreement with the University of British Columbia focusing on Major Depressive Disorder (MDD), often referred to as depression.

High Prevalence of Chronic Disease Such as Kidney around the Globe Is Driving the Growth of the Ioversol Market

 

Ioversol , otherwise known as IOU peroxide, is used as a dialysis anticoagulant in hospitals for the treatment of dialysis patients and is used commercially for the treatment of toothache. It is an oxidizing agent for internal applications in the human body. The Ioversol chemical name is Isoflavones and contains seven carbon atoms with one hydrogen atom in common with many substances derived from plants (Isoflavones). Isoflavones are commonly found in fruits such as strawberry and lemon, and also in egg yolk and some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally used for the relief of inflammation and to treat infections, to prevent or reduce bleeding, as dialysis therapy and to increase blood flow and oxygenate blood

The growing prevalence of bone-related disorders is a prime factor driving the growth of the ioversol market. Increasing geriatric population around the globe which is increasing the prevalence of the various chronic disease. This has raised the demand for a various diagnostic tool such as X-ray which is another key factor fueling the growth of the market. According to the United Nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The rise in spending on the healthcare sector by government for improving the patient care is further anticipated to propel the growth of the ioversol market.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the bone-related disorder in the region which. In 2017, the number of Canadians affected by osteoporosis had increased to 2 million. By the year 2030, the number of hip fractures is expected to quadruple. Moreover, In Canadians of 40 years or older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus the high prevalence of bone a related disorder is projected to foster the growth of the ioversol market.

Key Developments:

1.      In December 2020, Guerbet (GBT), a global provider of medical imaging, announced that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) (Ioversol Injection) in the United States.

Porcine Vaccines Market is Growing Robustly with Zoetis Inc. Receiving the European Commission Approval for its CircoMax Myco Vaccine Indicated for Porcine Circovirus Type 2 (PCV2) and Mycoplasma Hyopneumoniae in Pigs

 

The term "porcine vaccines" refers to the vaccines developed and used in animals, rather than in humans. The purpose of porcine vaccines is to protect farm animals from things like bacterial and viral diseases. The problem is that a lot of the viruses and bacteria that affect humans aren't infectious to animals, so it's difficult to develop vaccines against them. The two major types of porcine vaccines are Bovine Adverse Genomeopathy (BAG) and Meningitis. The former vaccine is more commonly known as the Meningitis vaccination; the latter is the Bago vaccine. Both vaccines prevent harmful viruses in the animals' bloodstream. However, they do have a few differences in how they work

Increasing demand for pork worldwide is expected to drive growth of the global porcine vaccines market. According to the Organisation for Economic Co-operation and Development (OECD), the total pork consumption in OECD countries reached 23.0 kilogram/capita in 2019, increasing from 22.1 kilograms/capita in 2010. The rise in pork consumption is attributed to the rapidly growing population and rising disposable incomes in emerging economies. Porcine vaccines can improve growth performance of pigs and prevent the spread of porcine parvovirus, mastitis, and more. Hence, these factors are expected to drive growth of the global porcine vaccines market. Furthermore, continuous research and development activities for the innovation of vaccines are expected to propel the global porcine vaccines market growth in the near future.

High expenses of maintaining and handling storage conditions combined with concerns regarding reverse reaction from vaccines are expected to restrain growth of the global porcine vaccines market. However, proactive government initiatives to develop novel vaccines can provide major business opportunities for key competitors in the near future. Among regions, North America is expected to witness significant growth in the global porcine vaccines market. This is owing to increasing demand for animal protein and growing expenditure on animal health by farm owners. Europe is expected to register a robust growth rate, owing to increasing demand for animal-based food products and rising awareness regarding porcine health as well recent advancements in the field of biotechnology.

Major companies involved in the global porcine vaccines market are Bayer AG, Zoetis Inc., IDT Biologika GmbH, Vetoquinol, HIPRA, Merial, Ceva Sante Animale, Intervet Inc., Elanco, and Arko Laboratories Ltd.

For instance, in December 2020, Zoetis Inc. received the European Commission approval for CircoMax Myco, a vaccine for pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.

Anti-counterfeit Pharmaceutical Packaging Market is Growing Rapidly with Toppan Printing collaborating with Amcor to provide NFC tag-based anti-counterfeiting solution

 

Pharmaceutical packaging for pharmaceuticals is made from a number of different materials, including plastics and glass. Most manufacturers will use plastic or glass for the packaging of their medications since it is the easiest and most cost-effective option available. However, there are those manufacturers that use other materials to develop their packaging for pharmaceuticals. Plastic and glass are used to create 'pressure boxes' and these manufacturers ensure that the boxes are manufactured to the highest quality standards possible. Each box is then packed with high-quality cardboard, which ensures that the packaging will withstand harsh environments.

Stringent laws and regulations enforced by governments are expected to drive growth of the global anti-counterfeit pharmaceutical packaging market. The government of many countries has enforced stringent regulations and laws to curb the counterfeiting of products. Furthermore, in September 2020, the International Trademark Association (INTA) announced to step up its efforts to combat counterfeit products with new laws under consideration. Moreover, in December 2019, in the U.S., the SANTA Act (Stopping All Nefarious Toys in America Act) was introduced that set requirements for online marketplaces selling toys to verify seller information and disclose it to consumers. Furthermore, in June 2020, Europol sized over 1,300 tons of fake pesticides, which could fill 458 Olympic-sized pools. Such factors are expected to drive growth of the global anti-counterfeit pharmaceutical packaging market. Furthermore, rising focus of manufacturers on brand protection is expected to boost the global anti-counterfeit pharmaceutical packaging market growth in the near future.

High initial cost combined with major R&D investment is expected to restrain growth of the global anti-counterfeit pharmaceutical packaging market. However, increasing demand from emerging economies and the availability of remote authentication of products technology can present lucrative growth opportunities in the global anti-counterfeit pharmaceutical packaging market. Among regions, North America is expected to witness significant growth in the global anti-counterfeit pharmaceutical packaging market. This is owing to the presence of stringent anti-counterfeit laws across the region. Furthermore, Europe is expected to register a robust growth rate, owing to the presence of prominent medical and pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Sanofi, Roche Ltd., and GlaxoSmithKline plc in the region.

Major companies involved in the global anti-counterfeit pharmaceutical packaging market are Zebra Technologies, Impinj, Inc., Alien Technology Corp., Microtrace, LLC, AlpVision, SICPA HOLDING SA, and Avery Dennison Corp.

For instance, in September 2019, Toppan Printing collaborated with Amcor to provide NFC tag-enabled anti-counterfeiting solutions for the wine and spirits market.

    

Impact of COVID-19 on Prescription Narcotic Cough Preparations and Expectorants Market 2021 Industry Size, Latest Trends, Worldwide Growth and Forecast Research Report 2027

 

High prevalence pertussis is expected to propel growth of the prescription narcotic cough preparations and expectorants market. For instance, according to the World Health Organization, there were 132,754 reported cases of pertussis worldwide in 2019. Moreover, high prevalence of chronic cough is also expected to aid in growth of the market. For instance, according to the study, ‘Prevalence and Characteristics of Chronic Cough in Adults Identified by Administrative Data’ published in Parmanente Journal in 2020, the overall prevalence was chronic cough was 1.04% in 2016. Moreover, the prevalence was higher in female patients than in male patients.

Permission for prescribing controlled substances through telemedicine is expected to offer lucrative growth opportunities for players in the prescription narcotic cough preparations and expectorants market. For instance, in 2020, the U.S. Drug Enforcement Administration permitted issuance of prescriptions for controlled substances via a telemedicine encounter in the wake of COVID-19 pandemic. Moreover, implementation of prescription drug monitoring programs is also expected to aid in growth of the market. Most states in the U.S. use an electronic database to help reduce misuse and diversion of controlled substances.

However, illicit sale of Codeine-based cough syrups is expected to hinder growth of the prescription narcotic cough preparations and expectorants market. The market is also witnessing increasing misuse of prescription and over-the-counter drugs for recreational purposes, thereby limiting its growth.

Ban or restrictions on manufacture, sale, and distribution of fixed dose combination drugs in some countries is also expected to limit the market growth. For instance, in 2018, the U.S. Food and Drug Administration advised against recommending cough medications that contain opioids to children.

The prescription narcotic cough preparations and expectorants market in North America is facing the challenge of pharmacy break-ins as narcotic cough preparations and expectorants cannot be acquired without a prescription. In February 2020, California Board of Pharmacy, U.S, stated that pharmacy break-ins increased from 114 in 2015 to 265 in 2018, recording a 49% increase. 

Competitive Analysis

Major players operating in the prescription narcotic cough preparations and expectorants market include, Glenmark Pharmaceuticals Ltd., Franklin Laboratories Pvt. Ltd., Pans Laboratories, Synokem Pharmaceuticals Ltd., Lyka Hetero Healthcare Limited, Biomedica International, Klar Sehen Pvt. Ltd., and Ciron Drugs & Pharmaceuticals Pvt. Ltd.

Increasing Global Healthcare Spending by Government is Propelling the Growth of the Pulmonary Arterial Hypertension (PAH) Market

 

Pulmonary Arterial Hypertension (PAH) is a disease that affects the vasculature of the heart, specifically the arteries that transport blood from the heart to the lungs. Common symptoms include heart palpitations or an irregular rhythm, chest pain, coughing, wheezing, shortness of breath, chest discomfort when breathing, and sometimes even heart failure. The cause of pulmonary hypertension is not known, but research has indicated that genetic and hormonal factors may play a role in its development.

The growing prevalence of Pulmonary Arterial Hypertension (PAH) is driving the growth of the Pulmonary Arterial Hypertension (PAH) Market. According to the European Respiratory Society, PAH is a rare disease, with an estimated prevalence ranging from 10 to 52 cases per million. The growing geriatric population is again increasing the prevalence of such disease which is also projected to foster the growth of the Pulmonary Arterial Hypertension (PAH) market. According to the United nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over.

North America is projected to gain significant growth over the forecast period and this is attributed to the growing adoption of advanced treatment for treating pulmonary arterial hypertension. Moreover, increasing spending by the government on the healthcare sector is again augmenting the regional market growth. According to the U.S. Centers for Medicare & Medicaid Services, National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach $6.2 trillion by 2028.

Key Developments:

1.      In September 2020, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI® (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults

2.      In September 2020, Alembic Pharmaceuticals announced that the subsidiary has received tentative approval from the US health regulator for Treprostinil injection indicated for the treatment of pulmonary arterial hypertension.

3.      In April 2019, Cipla has received final approval from the United States Food and Drug Administration (USFDA) for Ambrisentan used for pulmonary arterial hypertension drug

4.      In March 2019, Sandoz announced the US availability of Treprostinil Injection, the first fully substitutable AP rated generic version of Remodulin®* (treprostinil) Injection. Treprostinil is indicated for Pulmonary Arterial Hypertension (PAH)

Increasing advancement in the filling of formulations is expanding the prefilled syringes market size

 
The use of prefilled syringes for injection is becoming increasingly popular among physicians and healthcare providers. Prefilled syringes have many benefits over vial or penile injections: they are easier to inject, offer more consistent results, eliminate the need for a large an instrument to transfer a medication, and they do not require one person to administer the injection (which means there is a reduced risk of drug exposure or injury to staff during administration). Most prefilled syringes require the user to insert the syringe into a vial and then inject the contents of the vial into the tip of the syringe. In addition, some manufacturers have adopted the use of rubber cup lids to keep the syringe needle free from debris and to prevent injury to the fingers while pulling the plunger.

The growing prevalence of chronic disease around the globe coupled with the rising awareness regarding the benefits of the product is driving the growth of the prefilled syringes market. An increasing number of biologics and biosimilars in the pharmaceutical industry is again fueling the growth of the market. Technological advancement for developing superior quality products and filling procedures for ensuring stability in prefilled syringes is also projected to foster the growth of the prefilled syringes market. Benefits such as increased product life span and minimized drug wastage as compared to traditional methods are further anticipated to augment the growth of the prefilled syringes market.

On the other hand, complexities associated with prefilled syringes are projected to hinder the growth of the prefilled syringes market.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of diabetes which is driving demand for prefilled syringes. According to the American Diabetes Association, in 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents

Key Developments:

1.      In September 2018, Hikma Pharmaceuticals PLC (Hikma, Group) the multinational pharmaceutical company, has launched a new prefilled syringe capability in the US through its affiliate, Hikma Pharmaceuticals USA Inc. The first Hikma medicine available in prefilled syringe form is Heparin Sodium Injection, USP, 5000 Units/mL.

2.      In September 2019, Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling products, has launched a new tamper-evident security concept for luer-lock syringes. It features a combination of a cap adapter and label that firmly seals prefilled syringes for reliable first opening indication.

Increasing prevalence of infectious disease is predominantly augmenting the growth of the recombinant vaccines market

 

Recombinant vaccines are made by expressing live viruses as proteins and then creating DNA sequences out of these viruses. The proteins, or nucleic acid strands, of the virus, have been repaired with a polymerase that creates a piece of DNA identical to the rest of the viruses'. These DNA fragments, or polymers, are injected into the body of a susceptible individual, usually in a vein or in a garage, through the vein wall. This protects the patient against the deadly infection caused by the virus. Most commonly used vaccines require one dose of a product and one dose of a vaccine mixture. This is called a single dose schedule.

The high prevalence of infectious diseases around the globe is driving the recombinant vaccines market growth. According to the World Health Organization, infectious diseases kill over 17 million people a year. An increasing number of the manufacturer in the recombinant vaccines market is again propelling the growth of the market. Moreover, advancement in the development of technologies used in the production of vaccines is further anticipated to foster the growth of the recombinant vaccines market. Furthermore, continuous investment in research & development for the production of new vaccines are projected to fuel the growth of recombinant vaccines.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the infectious disease in the region. According to the National Center for Health Statistics, there were around new tuberculosis cases: 9,105, new salmonella cases: 54,285, new Lyme disease cases: 42,743, and new meningococcal disease cases: 353 in 2017.

Key Developments:

1.      In June 2020, Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.

2.      In November 2020, The European Commission has granted marketing authorization for Supemtek®, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older. Supemtek is the first and only recombinant influenza vaccine now approved in the European Union.

3.      In February 2020, scientists from Hong Kong and Macao special administrative regions announced a breakthrough in developing a recombinant COVID-19 vaccine indicating that the mass production of the vaccine is feasible at a low cost in the future.

The Global Shingles Vaccine Market Continues To Grow Owing To the Different Initiatives Taken By Governmental Bodies All Over the Globe and New Product Launches by Key Players

 

Shingles is a type of skin infection that is mainly caused by the reactivation of herpes zoster or chickenpox virus. Two vaccines till now have proven successful at reducing the chances of developing shingles. One is, Zostavax, which consists of a bigger-than-usual dose of the chickenpox vaccine since shingles and chickenpox are caused by the same virus, the varicella virus. The other vaccine is called Shinglesvax, consists of an adult shingles vaccine which has been proven to be effective in preventing younger children and adults from developing shingles. If someone develops shingles after receiving either of these, they need a varicella immune globulin vaccine. The shingles vaccine is made from a weakened chickenpox virus and when used in combination with symptoms specific to shingles, it greatly reduces the risks of developing the infection. However, there is a possibility of developing more serious side effects such as a rash or muscle pain. Rare side effects include feeling faint, nausea, blurred vision, and chest pain.

Market Dynamics                                  

The factor driving the growth of the shingles vaccine market is the increased prevalence of shingles worldwide. Moreover, the rising geriatric population and the high number of launches and approval of shingle vaccines are also estimated to trigger the market growth. For instance, in August 2019, experts from the Université Laval, Québec, and Centre de research du Centre Hospitalier de l'Université de Québec found that the Shingrix vaccine developed by GSK is very effective in terms of cost and treatment than the Zostavax developed by Merck & Co. The overall effectiveness of the vaccine was 97% and has a higher effectiveness rate among the geriatric population. Shingrix right now is the main competitor of Zostavax in the market. The growing rate of government initiatives and an increase in healthcare concerns are also driving the growth of the shingles vaccine market. However, the high cost of the shingle vaccines is acting as the main restraining factor hindering the growth of the market, especially in developing nations.

This market is distributed in five regions that include North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America. Among these, North America and Europe are estimated to hold a bigger share of the shingles vaccine market collectively. The market growth in North America is mainly driven by the increased demand for the vaccine in the U.S., while the European market is estimated to be driven by the growing demand of the European Union for therapeutic treatments.

The shingles vaccine market in the Asia Pacific is estimated to witness significant growth owing to the vast pharmaceutical market present in the region. Active marketing and differential pricing in regions such as India and China would aid the companies to strengthen the shingle vaccine market in the Asia Pacific.

Competitive Analysis

Major players operating in the shingles vaccine market include Curevo Inc., CanSino Biologics Inc., GlaxoSmithKline Plc, SK Bioscience, Vaccitech, Merck and Co. Inc., Inovio Pharmaceuticals, Inc, Sanofi, and Precision Vax LLC.

In May 2019, the National Medical Products Administration (NMPA) of China approved the Shingrix vaccine produced by GSK to prevent shingles in adults.

Approval and Launch of New Products and High Prevalence of Cancer to Augment Growth of Opioid Induced Constipation Treatment Market

 

Opioid-induced constipation (OIC) is caused by prolonged use of certain opioids, particularly for pain management. OIC may also be caused by taking long-term and excessive doses of narcotics with effects similar to dehydration, constipation, or nausea. OIC is a common condition affecting individuals with long-standing or steady use of powerful prescription pain medications like OxyContin, codeine and morphine, as well as individuals who take sedatives frequently or individuals who have other conditions like diarrhea, kidney or liver disease, or Crohn's disease.

Market Dynamics

Approval and launch of new products is expected to propel growth of the Opioid Induced Constipation Treatment Market. For instance, in September 2020, Sandoz, the generics division of Novartis AG, received a positive reimbursement decision in the UK for Rizmoic (naldemedine). The National Institute for Health and Care Excellence, U.K., issued a recommendation in favor of the option for treating opioid-induced constipation in adults, after previous laxative treatment. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

The Opioid Induced Constipation Treatment Market is witnessing launch of generic products. For instance, in January 2021, Par Pharmaceutical, Inc. launched the first authorized generic version of Amitiza, indicated for the treatment of chronic idiopathic constipation and opioid-induced constipation in adult with chronic non-cancer pain.

Decrease in opioid prescribing rates is expected to hinder growth of the Opioid Induced Constipation Treatment Market. For instance, according to the Centers for Disease Control and Prevention’s surveillance summaries published in January 2020, in the U.S. opioid prescribing rates declined in all 11 states during 2010–2016 (range: 14.9% to 33.0%).

The opioid-induced constipation treatment is witnessing several divesture activities. For instance, in February 2020, AstraZeneca agreed to sublicense its global rights to Movantik (naloxegol), a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of OIC, excluding Europe, Canada and Israel, to RedHill Biopharma.

Competitive Analysis

Major players operating in the Opioid Induced Constipation Treatment Market include, Daewoong Co. Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Cosmo Pharmaceuticals, AstraZeneca plc, Shionogi Inc., Abbott Laboratories, Valeant Pharmaceuticals, C.B. Fleet Company, Inc., and Bayer AG.

Major players operating in the Opioid Induced Constipation Treatment Market are focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in April 2019, BioDelivery Sciences, a Raleigh-based pharmaceutical company, acquired exclusive rights to commercialize an opioid-induced constipation drug in the U.S and Puerto Rico under a deal with Shinogi.